Dupilumab efficacy and safety in patients with moderate-to-severe COPD with type 2 inflammation: pooled analysis of BOREAS and NOTUS

被引：0
|
作者：
Bhatt, Surya [1 ]
Rabe, Klaus F. [2 ,3 ]
Hanania, Nicola [4 ]
Vogelmeier, Claus F. [5 ]
Bafadhel, Mona [6 ]
Christenson, Stephanie [7 ]
Papi, Alberto [8 ]
Singh, Dave [9 ]
Laws, Elizabeth [10 ]
Akinlade, Bolanle [11 ]
Maloney, Jennifer [11 ]
Lu, Xin [10 ]
Bauer, Deborah [10 ]
Bansal, Ashish [11 ]
Abdulai, Raolat M. [12 ]
Robinson, Lacey B. [12 ]
Bhatt, Surya [1 ]
机构：
[1] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA
[2] LungenClin Grosshansdorf, Grosshansdorf, Germany
[3] Christian Albrechts Univ Kiel, Airway Res Ctr North, German Ctr Lung Res, Grosshansdorf, Germany
[4] Baylor Coll Med, Dept Med, Sect Pulm & Crit Care Med, Houston, TX USA
[5] Univ Marburg, Dept Med Pulm & Crit Care Med, German Ctr Lung Res, Marburg, Germany
[6] Kings Coll London, Fac Life Sci & Med, Kings Ctr Lung Hlth, Sch Immunol & Microbial Sci, London, England
[7] Univ Calif San Francisco, Div Pulm Crit Care Allergy & Sleep Med, San Francisco, CA USA
[8] Univ Ferrara, Ferrara, Italy
[9] Manchester Univ NHS Fdn Trust, Univ Manchester, Manchester, England
[10] Sanofi, Bridgewater, NJ USA
[11] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[12] Sanofi, Cambridge, MA USA
来源：
EUROPEAN RESPIRATORY JOURNAL | 2024年 / 64卷
关键词：
D O I：
10.1183/13993003.congress-2024.PA4787
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
    Roh, Joo Young
    Park, Chun Wook
    Kim, Kyu Han
    Lee, Joo Hee
    Sun, Xian
    Rossi, Ana B.
    Shumel, Brad
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 53 - 53
  • [42] SAFETY AND EFFICACY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: AN ANALYSIS OF UP TO 100 WEEKS (LIBERTY AD OLE)
    Herranz, Pedro
    de la Cueva, Pablo
    Rodriguez Marco, Ainara
    Worrell, Richard
    Shumel, Brad
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 25 - 25
  • [43] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    Forman, Seth
    Soong, Weily
    Hussain, Iftikhar
    Bissonnette, Robert
    Bouaziz, Jean-David
    Gelfand, Joel
    Sher, Lawrence
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
  • [44] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
    Deleuran, M.
    Thaci, D.
    Beck, L.
    Forman, S.
    Soong, W.
    Hussain, I.
    Bissonnette, R.
    Bouaziz, J.
    Gelfand, J.
    Lawrence, S.
    Chen, Z.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Graham, N.
    Ardeleanu, M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
  • [45] Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial
    Castro, Mario
    Papi, Alberto
    Porsbjerg, Celeste
    Lugogo, Njira
    Brightling, Christopher
    Gonzalez-Barcala, Francisco-Javier
    Bourdin, Arnaud
    Ostrovskyy, Mykola
    Staevska, Maria
    Chou, Pai-Chen
    Duca, Liliana
    Pereria, Ana
    Fogarty, Charles
    Nadama, Rufai
    Zhang, Mei
    Rodrigues, Amelie
    Soler, Xavier
    Pantelimon, Simona
    Sacks, Harry
    Deniz, Yamo
    Rowe, Paul
    Gomez, Lucia De Prado
    Jacob-Nara, Juby
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB368 - AB368
  • [46] Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
    Wedzicha, Jadwiga A.
    Donaldson, Gavin
    Chuecos, Ferran
    Gil, Esther Garcia
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [47] Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials
    Wu, Shuying
    Wang, Huiping
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2022, 39 (03): : 601 - 610
  • [48] Impact of self-reported comorbid food allergy on efficacy and safety of abrocitinib and dupilumab in patients with moderate-to-severe atopic dermatitis: A pooled analysis of JADE COMPARE and JADE DARE
    Geng, B.
    Nosbaum, A.
    Boguniewicz, M.
    Vestergaard, C.
    Lazariciu, I.
    Feeney, C.
    Rebollo, F. J.
    Koppensteiner, H.
    Hernandez-Martin, I.
    ALLERGY, 2023, 78 : 140 - 140
  • [49] Dupilumab Induces Clinical Remission in Patients With Uncontrolled, Moderate-to-Severe, Type 2 Inflammatory Asthma
    Pavord, I. D.
    Israel, E.
    Szefler, S. J.
    Brusselle, G.
    Rabe, K. F.
    Chen, Z.
    Altincatal, A.
    Radwan, A.
    Pandit-Abid, N.
    Amin, N.
    Jacob-Nara, J. A.
    Rowe, P. J.
    Deniz, Y. M.
    Khan, A.
    Lederer, D. J.
    Zhang, Y.
    Busse, W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [50] Efficacy and safety of ensifentrine in European patients with moderate to severe COPD: pooled results from the ENHANCE trials
    Franssen, Frits M. E.
    Rheault, Tara
    Rickard, Kathleen
    Dixon, Amy
    Reyner, Daniel
    Watz, Henrik
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
12345